Bicara Therapeutics Inc

BCAX remains in a Stage 3 distribution with sequential lower highs and lower lows beneath declining 9/20/50 EMAs, reflecting supply dominance. Medium-term bias is bearish, favoring sell-side engagement on rallies into the EMA cluster. Short-term weakness and repeated rejection at overhead EMAs confirm immediate sell-now timing despite extreme oversold conditions.

• ↑13F ownership score of 1.90 indicates strong institutional backing.
• ↑Momentum score of 1.58 reflects one-year price outperformance.
• ↓Profitability score at –2.25 highlights weak operating margins.